A Patent Medicine Called Gatt

It wouldn't be surprising if Robert J. Gunter took a dose of his own medicine. President of generic drugmaker Novopharm USA Inc., he has spent five years gearing up to produce a generic version of Glaxo Holdings PLC's blockbuster ulcer drug, Zantac. He even invested $40 million in a plant in Wilson, N.C., built to pump out the low-cost version as soon as Glaxo's first patent expires in December.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.